Merck OTC abandoned due to the three major weak points-.docVIP

  • 8
  • 0
  • 约7.92千字
  • 约 7页
  • 2017-05-04 发布于浙江
  • 举报

Merck OTC abandoned due to the three major weak points-.doc

Merck OTC abandoned due to the three major weak points-

 PAGE \* MERGEFORMAT 7 Merck OTC abandoned due to ‘the three major weak points’? Have confidence in China’s OTC market, Germany’s Merck Pharmaceuticals, to enter the field in just over a year after more than a hastily ‘cease fire’, and by the end of March announced the sale of its production of OTC in China plant, equipment and plant stock, which and almost at the same time, high-profile announcement to enter the Chinese OTC market, in stark corresponding AstraZeneca. Merck’s move in the end is this so? ‘Market latecomers’ high-profile Merck has been raging in China OTC market is considered ‘late offensive’, but only after a year or more curtain call hastily hasty ending, with ‘the market late and leave early were’ to describe the Merck into China OTC no longer appropriate to the market. Merck’s high-profile areas of OTC into China began in 2003, culminated in October that year the company was chatting up Sinopharm Exhibition held 50th session of the National Drug Fair opportunity to host a super-100 in Chengdu participants ‘Merck China Station’ Merchants activity. I was just here, and seen Merck was confident performance. Merck to dealers describes a more detailed phased marketing plan, the outstanding feature is the brand marketing plus the terminal block. According to the plan, the first half of 2004 as the market period, the second half of the maintenance period for the market, it plans to use three years sufficient reserves ‘ammunition’ to take the attack to prepare the market, in the off market, to insist in the end to maintain its edge . Merck claims that its make no major brands, only the stronger brand, the pursuit of an immediate ‘soup’ to create and refused to fire ‘soup’ crash, when it is grown up and easy to shake his hard Han Shan. According to Merck, the original plan, the company produced 20 OTC drugs will enter the China market as a pioneer in the upcoming 4 varieties, respectively for the treatment of cough, fever, antipyretic and analg

文档评论(0)

1亿VIP精品文档

相关文档